BioSpace News Archive

President and CEO James Moe to participate in panel discussing preclinical small molecule drug discovery --

- Apple‡ smartphone-compatible digital health tool fits within the company’s broader NeuroSphere™ Digital Care connected care management platform, which is designed to optimize care for chronic pain and movement disorders - NeuroSphere Digital Care offers flexible virtual care options as the COVID-19 global pandemic impacts how healthcare is administered - Approval of the Patient Controller app is the latest launch under the NeuroSphere Digital Care(1) platform

EVERSANA™, the leading provider of global commercial services to the life sciences industry, announced a partnership with the Institute for Clinical and Economic Review to advance standards for the usage of transparent, replicable and robust indirect treatment comparisons in health technology assessments.

New research published in the European Journal of Nutrition finds that 100% orange juice reduces systolic blood pressure in adults with pre- or stage-1 hypertension

CSafe Global chose Cloudleaf to help deliver the company’s new digital visibility platform to support their track and trace technology and ensure 24/7 data access that will allow customers to make informed decisions and protect medicines for patients worldwide.

Apricorn, the leading manufacturer of software-free, 256-bit AES XTS hardware-encrypted USB 3.2 storage devices, has launched the Aegis Secure Key 3NXC – the first device of its kind with a USB-C connector

Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, announced today that Libbie Mansell, PhD, MBA, RAC, has joined the company as a senior vice president to lead its regulatory affairs operations. “Libbie’s career has spanned the development of small molecules and biologics. She has overseen nine global approvals for significant products, and she has created

Check-Cap Ltd. announced that it has entered into a definitive agreement with several existing institutional investors for the exercise of certain outstanding warrants to purchase up to an aggregate of 16,054,223 of its ordinary shares at a reduced exercise price of $0.60 per share.

Scott D. Flora appointed as Chairman of the Board.

Internationally renowned clinical-stage immune cell and gene therapy company, Gracell Biotechnologies Co., Ltd. (“Gracell” or “the Company”) has announced two appointments to the executive suite.